Adenocarcinoma of the Pancreas Completed Phase 2 Trials for Selumetinib (DB11689)

Also known as: Pancreatic adenocarcinoma / Adenocarcinoma Pancreas / Pancreas, Adenocarcinoma / Pancreas Adenocarcinoma / Adenocarcinoma of Pancreas / Adenocarcinoma, Pancreas

IndicationStatusPhase
DBCOND0029532 (Adenocarcinoma of the Pancreas)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01222689Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerTreatment